{"id":8450,"date":"2025-02-20T11:25:00","date_gmt":"2025-02-20T11:25:00","guid":{"rendered":"https:\/\/heliospectra.com\/blog\/mfn_news\/heliospectra-publishes-information-memorandum-in-connection-with-the-rights-issue\/"},"modified":"2025-10-24T09:20:49","modified_gmt":"2025-10-24T09:20:49","slug":"heliospectra-publishes-information-memorandum-in-connection-with-the-rights-issue","status":"publish","type":"mfn_news","link":"https:\/\/heliospectra.com\/nl\/blog\/mfn_news\/heliospectra-publishes-information-memorandum-in-connection-with-the-rights-issue\/","title":{"rendered":"Heliospectra Publishes Information Memorandum in Connection with The Rights Issue"},"content":{"rendered":"
Gothenburg, Sweden, February 20, 2025, at 12:25 CET – Heliospectra AB (publ) (the “Company”) has prepared an information memorandum in Swedish (the “Memorandum”) in connection with the new issue of shares resolved by the Board of Directors on January 23, 2025, and approved by the extraordinary general meeting on February 12, 2025 (the “Rights Issue”). The Memorandum is available on the Company’s website, www.heliospectra.com, along with other information related to the Rights Issue.<\/strong><\/div>\n

The Board of Directors resolved on January 23, 2025, conditional on approval of an extra ordinary general meeting, to carry out a new share issue of up to approximately SEK 25.6 million with preferential rights for existing shareholders. The extraordinary general meeting on February 12, 2025, resolved to approve the Rights Issue. Complete information, terms, and instructions regarding the Rights Issue can be found in the Memorandum. The Memorandum is only available in Swedish and since February 19 available on Heliospectra’s website, www.heliospectra.com.<\/span><\/span><\/span><\/span><\/p>\n

Indicative time plan <\/strong><\/span><\/span><\/span><\/span><\/p>\n

The following time plan for the Rights Issue is preliminary and subject to change. <\/span><\/span><\/span><\/span><\/p>\n\n\n\n\n\n\n
Trading in share rights<\/span><\/span><\/span><\/span><\/td>\n19 February 2025 – 28 February 2025<\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n
Subscription period<\/span><\/span><\/span><\/span><\/td>\n19 February 2025 – 5 March 2025<\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n
Trading in paid subscribed shares (BTA)<\/span><\/span><\/span><\/span><\/td>\n19 February 2025 – week 12 2025<\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n
Expected announcement of the outcome in the Rights Issue<\/span><\/span><\/span><\/span><\/td>\n6 March 2025<\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\nAdvisers<\/strong><\/span><\/span><\/span><\/span><\/p>\n

MAQS Advokatbyrå AB is legal adviser to the Company in connection with the Rights Issue and Aqurat Fondkommission AB is issuing agent in the Rights Issue.<\/span><\/span><\/span><\/span><\/p>\n

\n

For More Information:<\/strong><\/span><\/span><\/p>\n

Rebecca Nordin, Head of IR at Heliospectra | +46 (0)72 536 8116 | ir@heliospectra.com<\/a><\/span><\/span><\/p>\n

http:\/\/www.heliospectra.com<\/a><\/span><\/span><\/p>\n<\/div>\n